Inhibition of human chondrosarcoma cell growth via apoptosis by peroxisome proliferator-activated receptor-γ

[1]  K. Tominaga,et al.  Ligand for peroxisome proliferator-activated receptor-Γ inhibits proliferation and induces apoptosis of barrett's adenocarcinoma both in vitro and in vivo , 2003 .

[2]  F. Sim,et al.  Chondrosarcoma of the Pelvis: A Review of Sixty-four Cases , 2001, The Journal of bone and joint surgery. American volume.

[3]  T. Kawaguchi,et al.  Involvement of p21WAF1/Cip1, p27Kip1, and p18INK4c in troglitazone‐induced cell‐cycle arrest in human hepatoma cell lines , 2001 .

[4]  H. Inoue,et al.  Involvement of nitric oxide in chondrocyte cell death in chondro-osteophyte formation. , 2001, Osteoarthritis and cartilage.

[5]  T. Kawaguchi,et al.  Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. , 2001, Hepatology.

[6]  T. Terada,et al.  PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. , 2000, International journal of oncology.

[7]  T. Okura,et al.  Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells. , 2000, European journal of pharmacology.

[8]  S. Ishihara,et al.  Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists , 2000, British Journal of Cancer.

[9]  T. Okumura,et al.  Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. , 2000, Cancer research.

[10]  B. Spiegelman,et al.  Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[11]  J. Vamecq,et al.  Evolutionary aspects of peroxisomes as cell organelles, and of genes encoding peroxisomal proteins , 2000, Biology of the cell.

[12]  J. Magdalou,et al.  Evidence for the Presence of Peroxisome Proliferator-activated Receptor (PPAR) α and γ and Retinoid Z Receptor in Cartilage , 2000, The Journal of Biological Chemistry.

[13]  M. Kondo,et al.  Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. , 2000, Biochemical and biophysical research communications.

[14]  T. Chang,et al.  Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. , 2000, Cancer research.

[15]  J. Magdalou,et al.  Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes. , 2000, The Journal of biological chemistry.

[16]  V. Seewaldt,et al.  Peroxisome proliferator-activated receptor gamma activation in human breast cancer. , 1999, International journal of oncology.

[17]  M. Mitchell,et al.  15-Deoxy-Delta(12,14)-prostaglandin J(2), a ligand for peroxisome proliferator-activated receptor-gamma, induces apoptosis in JEG3 choriocarcinoma cells. , 1999, Biochemical and biophysical research communications.

[18]  T. Okumura,et al.  Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells , 1999 .

[19]  R. Morrison,et al.  Role of PPARγ in Regulating a Cascade Expression of Cyclin-dependent Kinase Inhibitors, p18(INK4c) and p21(Waf1/Cip1), during Adipogenesis* , 1999, The Journal of Biological Chemistry.

[20]  B. Spiegelman,et al.  Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Y. Matsuzawa,et al.  Peroxisome Proliferator‐activated Receptor γ Induces Growth Arrest and Differentiation Markers of Human Colon Cancer Cells , 1999, Japanese journal of cancer research : Gann.

[22]  T. Okumura,et al.  Activation of PPARgamma inhibits cell growth and induces apoptosis in human gastric cancer cells. , 1999, FEBS letters.

[23]  John Calvin Reed,et al.  Investigation of glucocorticoid-induced apoptotic pathway: Processing of Caspase-6 but not Caspase-3 , 1998, Cell Death and Differentiation.

[24]  C. Glass,et al.  Nuclear Integration of Glucocorticoid Receptor and Nuclear Factor-κB Signaling by CREB-binding Protein and Steroid Receptor Coactivator-1* , 1998, The Journal of Biological Chemistry.

[25]  H. Inoue,et al.  A new human chondrosarcoma cell line (OUMS‐27) that maintains chondrocytic differentiation , 1998, International journal of cancer.

[26]  Samuel Singer,et al.  Differentiation and reversal of malignant changes in colon cancer through PPARγ , 1998, Nature Medicine.

[27]  H P Koeffler,et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. , 1998, Cancer research.

[28]  H P Koeffler,et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  P. Herrlich,et al.  Transcriptional cross-talk, the second mode of steroid hormone receptor action , 1998, Journal of Molecular Medicine.

[30]  A. Levine.  p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.

[31]  B. Spiegelman,et al.  Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Yasko,et al.  Chondrosarcoma of the pelvis: Prognostic factors for 67 patients treated with definitive surgery , 1996, Cancer.

[33]  Thorsten Heinzel,et al.  A CBP Integrator Complex Mediates Transcriptional Activation and AP-1 Inhibition by Nuclear Receptors , 1996, Cell.

[34]  W. Winkelmann,et al.  Influence of intralesional surgery on treatment outcome of chondrosarcoma , 1996, Cancer.

[35]  M. Lazar,et al.  Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. , 1994, Endocrinology.

[36]  F. Schajowicz.  Tumors and Tumorlike Lesions of Bone , 1994, Springer Berlin Heidelberg.

[37]  K. Umesono,et al.  Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors , 1992, Nature.

[38]  M. Romsdahl,et al.  Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading , 1977, Cancer.